Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.

Epigenetic regulators can modulate the effects of cancer therapeutics. To further these observations, we discovered that the bromodomain PHD finger transcription factor subunit (BPTF) of the nucleosome remodeling factor (NURF) promotes resistance to doxorubicin, etoposide, and paclitaxel in the 4T1 breast tumor cell line. BPTF functions in promoting resistance to doxorubicin and etoposide, but not paclitaxel, and may be selective to cancer cells, as a similar effect was not observed in embryonic stem cells.

WITHDRAWN: The chromatin remodeling complex NURF localizes to gene bodies and is required for mRNA processing.

This article has been withdrawn by Aiman Alhazmi, Marissa Mack, Tiffany Rolle, Jordan Hiegel, Syed Haqqani, Nga Dao, Farheen Zaman, Nak-Kyeong Kim, Neel Scarsdale, Charles Lyons, and Joseph Landry. Some of the genome-wide data sets were flawed and were not analyzed correctly. The withdrawing authors are in the process of correcting the data sets and re-analyzing them for resubmission.

Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity.

Cancer chemotherapeutic drugs have greatly advanced our ability to successfully treat a variety of human malignancies. The different forms of stress produced by these agents in cancer cells result in both cell autonomous and cell nonautonomous effects. Desirable cell autonomous effects include reduced proliferative potential, cellular senescence, and cell death.